Any Coronary Artery Calcium in Early Adulthood Ups CV Risk

Share this content:
Any Coronary Artery Calcium in Early Adulthood Ups CV Risk
Any Coronary Artery Calcium in Early Adulthood Ups CV Risk

THURSDAY, Feb. 9, 2017 (HealthDay News) -- Coronary artery calcium (CAC) is associated with coronary heart disease (CHD) and cardiovascular disease (CVD) among younger adults, according to a study published online Feb. 8 in JAMA Cardiology.

John Jeffrey Carr, M.D., from Vanderbilt University Medical Center in Nashville, Tenn., and colleagues used data from a prospective study involving 5,115 black and white participants aged 18 to 30 years who were under surveillance for 30 years. CAC was measured at 15, 20, and 25 years after recruitment. Incident events were assessed during a mean follow-up of 12.5 years from the year 15 computed tomographic scan (3,043 participants) through 2014.

The researchers found that 10.2 percent of participants had CAC at year 15 of the study. During follow-up, there were 57 incident CHD events and 108 incident CVD events. Participants with any CAC experienced an increase in CHD and CVD events (hazard ratios, 5.0 and 3.0, respectively), in adjusted analysis. The hazard ratios for CHD were 2.6, 5.8, and 9.8, respectively, within CAC score strata of 1 to 19, 20 to 99, and ≥100. The incidence of deaths was 22.4 per 100 participants with a CAC score of 100 or more (hazard ratio, 3.7); 10 of the 13 deaths in participants with a CAC score of ≥100 were adjudicated as CHD events.

"Selective use of screening for CAC might be considered in individuals with risk factors in early adulthood to inform discussions about primary prevention," the authors write.

Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »